These transgenic mice express the mouse Il7 (interleukin-7) gene under the control of the mouse H2-Ea (histocompatibility 2, class II antigen E alpha) promoter. The transgene is overexpressed in MHC class II positive including the medullary thymic epithelium and B lymphocytes.
25% of transgenic mice on a C57BL/6 background develop lymphoid tumors and tumor incidence increases with age. Lymphoproliferative disorder is detected in mutant mice as young as 6 weeks of age (enlarged lymph nodes, remodeled bone, predominance of lymphoid cells in bone marrow cavity, increased number of circulating lymphoid cells). The majority of tumors occur in mice 4 to 6 months of age. The number of follicular B cells is significantly increased but the number of marginal zone B cells remains constant in transgenic mice. The total number of T cells is increased 10 to 20 fold. Homozygotes are viable, however, homozygous males have reduced lifespan due to lymphoma development. This mutant mouse strain may be useful in studies of T lymphocyte homeostasis, memory T cell development, B cell lymphoma, lymphoproliferative disorder, B lymphopoiesis, B cell development, post-translational histone modifications and chromatin remodeling.

These transgenic mice overexpress the mouse Il7 (interleukin-7) gene under the control of the mouse H2-Ea (histocompatibility 2, class II antigen E alpha) promoter, and approximately 25% develop lymphoid tumors. This mutant mouse strain may be useful in studies of B cell lymphoma, lymphoproliferative disorder, B lymphopoiesis, B cell development, post-translational histone modifications and chromatin remodeling.

Typically mice are recovered in 12-16 weeks. Contact Customer Service to place an order or for more information.

<a target="_blank" href="https://www.jax.org/jax-mice-and-services/customer-support" rel="noreferrer">Contact Customer Service</a> for more information.